vTv Therapeutics Inc (NASDAQ:VTVT) shares gapped up before the market opened on Friday following insider buying activity. The stock had previously closed at $1.79, but opened at $1.65. vTv Therapeutics shares last traded at $1.59, with a volume of 14828 shares trading hands.
Specifically, major shareholder Ronald O. Perelman acquired 1,358,698 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average price of $1.84 per share, with a total value of $2,500,004.32. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ronald O. Perelman acquired 815,217 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were purchased at an average cost of $1.84 per share, with a total value of $1,499,999.28. The disclosure for this purchase can be found here. Corporate insiders own 1.70% of the company’s stock.
Several equities research analysts recently weighed in on VTVT shares. Zacks Investment Research cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating and set a $2.75 price objective for the company. in a research report on Saturday, January 19th. Northland Securities reaffirmed a “hold” rating and set a $3.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, February 27th.
The stock has a market capitalization of $73.47 million, a price-to-earnings ratio of -2.32 and a beta of -3.79.
vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.26) EPS for the quarter. The firm had revenue of $0.92 million for the quarter. As a group, sell-side analysts anticipate that vTv Therapeutics Inc will post -0.59 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Barclays PLC increased its position in vTv Therapeutics by 366.7% during the 4th quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 22,000 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in vTv Therapeutics during the 4th quarter valued at approximately $186,000. Wedbush Securities Inc. acquired a new stake in shares of vTv Therapeutics during the 1st quarter worth approximately $30,000. Sabby Management LLC acquired a new stake in shares of vTv Therapeutics during the 1st quarter worth approximately $382,000. Finally, Morgan Stanley grew its position in shares of vTv Therapeutics by 147,061.5% during the 1st quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock worth $33,000 after buying an additional 19,118 shares during the period. 1.16% of the stock is owned by hedge funds and other institutional investors.
About vTv Therapeutics (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Featured Article: Portfolio Manager
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.